SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jenburkt Pharmaceuticals board to consider dividend

19 May 2016 Evaluate

Jenburkt Pharmaceuticals has informed that a Meeting of Board of Directors of the Company is scheduled to be held on May 30, 2016, to consider and take on record the audited results for the quarter / financial year ended on March 31, 2016; and to recommend Dividend, if any.

The above information is a part of company’s filings submitted to BSE.

Jenburkt Pharma Share Price

1044.65 19.05 (1.86%)
20-Apr-2026 15:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.50
Dr. Reddys Lab 1233.20
Cipla 1232.00
Zydus Lifesciences 937.70
Lupin 2327.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×